Nosokomeio Paidon I Agia Sofia

The Cardiology Department at Nosokomeio Paidon I Agia Sofia is advancing novel diagnostic tools and therapeutic devices to improve patient monitoring and treatment delivery.

• Development of pediatric pharmacokinetic profiling for targeted therapies
• Implementation of advanced imaging for early detection of cardiac anomalies
• Evaluation of new device-based drug delivery systems in children

These efforts aim to refine precision medicine approaches across multiple disease areas.

Clinical studies focus on complicated urinary tract infections and acute pyelonephritis in pediatric patients, testing newer antimicrobial regimens.

• Assessment of meropenem‑vaborbactam safety in children
• Comparison of treatment durations for acute pyelonephritis
• Exploration of resistance patterns to guide therapy

The goal is to enhance outcomes and reduce recurrence of severe bacterial infections.

Research targets heart failure due to left ventricular systolic dysfunction and familial hypercholesterolemia, evaluating novel agents and combination therapies.

• Long‑term safety of finerenone added to ACE inhibitors
• Impact on proteinuria and NT‑proBNP levels
• LDL‑C reduction with inclisiran in heterozygous familial hypercholesterolemia

These trials seek to improve cardiac function and reduce cardiovascular risk in children and adolescents.

Studies address growth disorders such as Turner syndrome, Noonan syndrome, and short stature, comparing growth hormone regimens.

• Weekly somapacitan versus daily Norditropin® effectiveness
• Height velocity outcomes across different growth indications
• Safety monitoring of long‑term hormone therapy

The aim is to support optimal growth trajectories in affected children.

The site conducts trials on inflammatory bowel disease, including Crohn’s disease and ulcerative colitis, testing biologics and small molecules.

• Vedolizumab maintenance therapy efficacy
• Upadacitinib for clinical remission and endoscopic response
• Evaluation of mucosal healing with novel agents

These investigations aim to achieve durable remission and improve quality of life for pediatric patients.

Ongoing research evaluates treatments for hemophilia and thalassemia, focusing on prophylaxis and transfusion reduction.

• Concizumab prophylaxis effectiveness in hemophilia A/B with inhibitors
• SP‑420 dose‑response in transfusion‑dependent α/β‑thalassemia
• Mitapivat impact on anemia in non‑transfusion‑dependent thalassemia

The objective is to lessen bleeding episodes and transfusion burden while enhancing patient safety.

Clinical trials aim to improve management of congenital adrenal hyperplasia and related endocrine disorders.

• Crinecerfont efficacy in reducing adrenal steroid levels
• Pharmacokinetic profiling of new hormone modulators
• Safety monitoring of long‑term endocrine therapy

These studies seek to provide better hormonal control and reduce disease complications.

Investigations focus on autoimmune conditions such as Behçet’s disease and juvenile idiopathic arthritis, testing targeted immunomodulators.

• Apremilast long‑term safety in Behçet’s oral ulcers
• Sarilumab dosing for systemic juvenile idiopathic arthritis
• Filgotinib efficacy in polyarticular‑course juvenile idiopathic arthritis

The goal is to control inflammation, reduce flare frequency, and improve functional outcomes.

Trials target muscular dystrophies and related disorders, evaluating gene‑based and anti‑inflammatory therapies.

• Vamorolone safety regarding vertebral fractures in Duchenne muscular dystrophy
• Viltolarsen intravenous dosing in boys with DMD
• Assessing functional improvement with novel anti‑fibrotic agents

These efforts aim to preserve muscle strength and delay disease progression.

The department participates in pediatric oncology studies for neuroblastoma, ependymoma, and rhabdomyosarcoma, exploring intensified chemotherapy and immunotherapy.

• High‑dose chemotherapy versus tandem regimens in high‑risk neuroblastoma
• CAR‑T cell therapy safety and efficacy in hematologic malignancies
• Targeted RAF inhibition in low‑grade glioma

Objectives include improving event‑free survival and reducing late sequelae.

Research addresses iron overload and metabolic complications in thalassemia and sickle cell disease, testing chelation and metabolic modulators.

• REGN7999 subcutaneous dosing for iron overload reduction
• Etavopivat efficacy in sickle cell disease anemia management
• Rilzabrutinib prevention of vaso‑occlusive crises

The aim is to improve organ health and reduce disease‑related complications.

Studies evaluate biomarkers and clinical signs such as proteinuria and renal dysfunction in chronic kidney disease.

• Finerenone impact on urine protein excretion
• Long‑term safety of finerenone combined with ACEI/ARB
• Assessment of renal outcomes in pediatric heart failure patients

These trials seek to mitigate renal injury and enhance overall patient prognosis.